Atherosclerosis

1995

DOI: 10.1016/0021-9150(95)96307-e

|View full text |Cite

|

Sign up to set email alerts

|

Malondialdehyde-modified low density lipoproteins in patients with atherosclerotic disease

¹

,

Guido O. Pérez²,

Zhenjuan Zhao³

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Lipoproteins: Isolation and Modification3

Discussion1

Assays1

Citation Types

Supporting

8

Mentioning

114

Contrasting

1

Unclassified

5

Year Published

1996

1996

2015

2015

Publication Types

Select...

Article7

Relationship

Self Cite0

Independent7

Authors

Journals

Cited by 86 publications

(128 citation statements)

References 0 publications

Supporting

8

Mentioning

114

Contrasting

1

Unclassified

5

Order By: Relevance

“…Holvoet et al (15) have shown significantly increased level of MDA in patients of atheroscerosis. Subsequently many immunologial techniques.…”

Section: Discussionmentioning

confidence: 95%

Oxidised LDL, HDL cholesterol, LDL cholesterol levels in patients of coronary artery disease

¹

,

²

,

³

et al. 2006

Indian J Clin Biochem

View full text Add to dashboard Cite

Coronary artery disease is a major cause of morbidity and has various risk factors. Lipid profile i.e. low HDL-cholesterol, high LDL cholesterol, high total cholesterol, high triglycerides playing important role in its causation. Recently interest has been shown in the oxidized fraction of LDL as one of the risk factors. In the present study 60 age and sex matched normal healthy individuals were taken as controls and 60 patients of CAD were taken. Cholesterol was measured by enzymatic method, HDL cholesterol by phosphotungstate precipitation method. Serum levels of LDL fraction of cholesterol was measured by a new and simpler method of precipitation. Result was expressed as mol/L of diene conjugates. It was observed that LDL cholesterol, VLDL cholesterol, total cholesterol, total cholesterol:HDL cholesterol, LDL cholesterol:HDL cholesterol were significantly raised and HDL cholesterol was significantly low in patients. (p< 0.001). Though HDL cholesterol was significantly raised in females as compared to males in both the groups (p<0.001). Serum level of total cholesterol, oxidized LDL:HDL cholesterol were also raised significantly (p<0.05). The level of oxidized LDL showed an increasing trend in patients.

“…Holvoet et al (15) have shown significantly increased level of MDA in patients of atheroscerosis. Subsequently many immunologial techniques.…”

Section: Discussionmentioning

confidence: 95%

Oxidised LDL, HDL cholesterol, LDL cholesterol levels in patients of coronary artery disease

¹

,

²

,

³

et al. 2006

Indian J Clin Biochem

View full text Add to dashboard Cite

Coronary artery disease is a major cause of morbidity and has various risk factors. Lipid profile i.e. low HDL-cholesterol, high LDL cholesterol, high total cholesterol, high triglycerides playing important role in its causation. Recently interest has been shown in the oxidized fraction of LDL as one of the risk factors. In the present study 60 age and sex matched normal healthy individuals were taken as controls and 60 patients of CAD were taken. Cholesterol was measured by enzymatic method, HDL cholesterol by phosphotungstate precipitation method. Serum levels of LDL fraction of cholesterol was measured by a new and simpler method of precipitation. Result was expressed as mol/L of diene conjugates. It was observed that LDL cholesterol, VLDL cholesterol, total cholesterol, total cholesterol:HDL cholesterol, LDL cholesterol:HDL cholesterol were significantly raised and HDL cholesterol was significantly low in patients. (p< 0.001). Though HDL cholesterol was significantly raised in females as compared to males in both the groups (p<0.001). Serum level of total cholesterol, oxidized LDL:HDL cholesterol were also raised significantly (p<0.05). The level of oxidized LDL showed an increasing trend in patients.

“…10 Characterization of modified LDL involved measurement of thiobarbituric acid-reactive substances, determination of electrophoretic mobility on 1% agarose gels, quantification of cholesterol and fatty acids by high-performance liquid chromatography on a Nova-Pak C18 reversed-phase column (Waters Associates), and quantification of proteins by Lowry assay and of phospholipids by enzymatic assay (Biomérieux). 18 Oxidized LDLs were isolated from the purified LDL fractions of patients by fast flow chromatography on a mono-QSepharose column. 18 The apo B-100 molecules of in vitro MDAmodified LDL and of copper-oxidized LDL contained on average 244 and 210 substituted lysines (from a total of 356), respectively.…”

Section: Lipoproteins: Isolation and Modificationmentioning

confidence: 99%

“…18 Oxidized LDLs were isolated from the purified LDL fractions of patients by fast flow chromatography on a mono-QSepharose column. 18 The apo B-100 molecules of in vitro MDAmodified LDL and of copper-oxidized LDL contained on average 244 and 210 substituted lysines (from a total of 356), respectively. [17][18][19] Whereas the extent of lysine substitution in in vitro MDA-modified LDL and copper-oxidized LDL is very similar, the lipid moiety in in vitro MDA-modified LDL is not oxidized.…”

Section: Lipoproteins: Isolation and Modificationmentioning

confidence: 99%

“…18 The apo B-100 molecules of in vitro MDAmodified LDL and of copper-oxidized LDL contained on average 244 and 210 substituted lysines (from a total of 356), respectively. [17][18][19] Whereas the extent of lysine substitution in in vitro MDA-modified LDL and copper-oxidized LDL is very similar, the lipid moiety in in vitro MDA-modified LDL is not oxidized. We have demonstrated that the specificity of the mAb E6 depends on the extent of protein modification only.…”

Section: Lipoproteins: Isolation and Modificationmentioning

confidence: 99%

“…10,18 Immobilized antigens for this assay included native LDL prepared from pooled human plasma (protected against in vitro oxidation as described above), copper-oxidized and MDA-modified LDL, and human serum albumin. The plasma samples were diluted 40-fold and incubated for 2 hours at room temperature in the coated microtiter plates.…”

Section: Assaysmentioning

confidence: 99%

See 2 more Smart Citations

Oxidized Low Density Lipoproteins in Patients With Transplant-Associated Coronary Artery Disease

¹

,

²

,

³

et al. 1998

View full text Add to dashboard Cite

Abstract-The monoclonal antibody 4E6 -based ELISA was used to quantify levels of oxidized LDL in plasma of 65 control subjects, 47 patients transplanted for dilated cardiomyopathy (DCM), and 60 patients transplanted for coronary artery disease (CAD). Levels of oxidized LDL were 0.68Ϯ0.039 mg/dL (meanϮSEM), 1.27Ϯ0.14 mg/dL (PϽ.001 versus control), and 1.73Ϯ0.13 mg/dL (PϽ.001 versus control and Ͻ0.01 versus DCM), respectively. Levels of oxidized LDL were significantly lower in transplanted patients with angiographically normal coronary arteries (grade 0, T he development of CAD after cardiac transplantation is a leading cause of graft failure in recipients who survive the first year after surgery. 1,2 This posttransplant arteriopathy is characterized by rapid development, 3,4 concentric narrowing of smaller coronary arteries, 5,6 and the lack of correlation with known atherogenic risk factors. [1][2][3][4][5][6] Understanding the etiology of accelerated atherosclerosis might allow identification of patients at risk for this complication.It has been suggested that ischemic injury of the heart during the peritransplant period significantly contributes to the development of accelerated atherosclerosis in heart transplant patients. 7 A correlation between LDL oxidation and atherogenesis was first suggested by experiments showing that oxidized LDL mediated injury to endothelial cells (reviewed in Reference 8) and was further supported by studies showing a protective effect of antioxidants against progression of atherosclerosis. 9 The study of the correlation between oxidized LDL and atherosclerosis has, however, been hampered by the lack of a sensitive and specific assay for oxidized LDL in plasma. In the present study we have used an ELISA that is highly specific for oxidized LDL. 10 The ELISA was used to study the association between plasma levels of oxidized LDL and CAD. Methods PatientsThe posttransplant study group contained 47 patients transplanted for DCM and 60 patients treated for CAD. The clinical characteristics of these patients are summarized in Table 1. At the time of blood sampling, between 12 and 84 months after surgery, all patients were in a stable cardiac condition without evidence of acute rejection. Adequate information about the smoking habits was available for 92 of the 107 patients (16 smokers and 76 nonsmokers). There was no adequate information about smoking habits of donors. Rejection was graded by the histopathologic classification of the International Society for Heart and Lung Transplantation. Rejections Ն grade 3A were treated. Maintenance immunosuppression consisted of triple-drug therapy including cyclosporin, azathioprine, and prednisone. Rejection episodes were treated with high-dose intravenous corticosteroids and steroid-resistant rejection with a course of OKT3, a murine anti-CD3 mAb. 11 Cytomegalovirus infection was defined as seroconversion of a seronegative recipient or a fourfold rise in titer postoperatively in a previously cytomegalovirus-positive recipient.Blood samples of 6...

Malondialdehyde-Modified LDL as a Marker of Acute Coronary Syndromes

¹

,

1999

View full text Add to dashboard Cite

Drs Holvoet and Collen are staff members of the University of Leuven and inventors of the assay for malondialdehyde-modified lowdensity lipoprotein, for which patent applications have been filed in Europe and the United States. All rights on inventions made by members of the University of Leuven are vested by Leuven Research and Development, the technology transfer unit of the University of Leuven, which also will receive any royalties.

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

hi@scite.ai

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

Product

Browser Extension Assistant by scite Citation Statement Search Reference Check Visualizations Dashboards Explore Journals Explore Organizations Explore Funders Embedding Badge Embedding Citation Search Pricing

Resources

Blog Help & FAQ Accessibility Statement API Terms For Universities & Governments For Researchers For Publishers For Corporate, Pharma & Enterprise Author Marketing Become an Affiliate Get an organization trial or quote scite Data & Services

About

News & Press Careers Read our Paper Coverage

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Copyright © 2024 scite LLC. All rights reserved.

Made with 💙 for researchers

Part of the Research Solutions Family.